QNTM

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the "Company"), the company behind unbuzzd™, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commercialization strategy. With the functional beverage market projected to reac

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has largely ruled against defendants CIBC World Markets ("CIBC") and RBC Dominion Securities ("RBC") joint motion to dismiss Quantum Biopharma's lawsuit alleging illegal market manipulation. The Quantum Biopharma lawsuit alleges that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used "spoofing" techniques to manipul

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate update. The Company announces the grant of 35,000 stock options (the "Stock Options") to certain employees, and consultants. Each option granted vests immediately and is exercisable at a price of CA$6.50 for a period of five years from

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Quantum's strong balance sheet and overall progress continue, and management is confident that there is sufficient working capital, as of the date of filing these Financial Statements, to carry out its operations over the next 24 mont

20-F - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator for its planned Phase 2 clinical trial evaluating Lucid-21-302 (Lucid-MS), an investigational therapy being developed to target demyelination in Multiple Sclerosis (MS). Dr. Salvatore Napoli, is an internationally recognized neurologist and key opinion leader in MS, with over 20 years of clinical and research experience. He is President and Medical Director

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced the peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product, ‘unbuzzd', comprising of a proprietary blend of vitamins and supplements developed by a world-class team of scientists at Quantum BioPharma. The trial, which investigated the effects of unbuzzd on alcohol intoxication and alcohol metabolism, was published here in

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that it has closed an initial tranche ("First Tranche") of the offering announced on March 10, 2026 and March 11, 2026 (collectively, the "Announcement NRs") and has issued 3,750 Debenture Units (as defined in the Announcement NRs) for $3,750,000. The Company will use the proceeds from the First Tranche for the ongoing development of the Company's busine

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.  TORONTO, March 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that it will release its financial and operational results for the quarter and year ended December 31, 2025, after financial markets close on March 24, 2026. The Company's fourth fiscal quarter and year end 2025 financial and operational results will be available on SEDAR+, EDGAR, and on the Company's website at https://www.quantumbiopharma.com/investors.

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces that oral dosing of Lucid-21-302 (Lucid-MS) is complete in both the 180-day toxicity and toxicokinetic studies. These studies will support the Investigational New Drug (IND) application with the US FDA, including the design of a Phase 2 trial of Lucid-MS i

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

424B5 - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, ONTARIO / ACCESS Newswire / December 22, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"),understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.A link to this complaint can be found here.Quantum Biopharma intends to seek appointment as a lead plaintiff in this class action in order to assist in protecting its shareholders.F

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K/A - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)